• Mashup Score: 0
    Neutrophil-activating therapy for the treatment of cancer - 1 year(s) ago

    Linde et al. describe a cancer therapy that activates neutrophils to infiltrate and eradicate tumors and reduce metastatic seeding. The authors elucidate the responsible mechanism, which involves complement component C5a, leukotriene B4, and reactive oxygen species, and demonstrate the potential of harnessing neutrophils through inflammatory activation to drive tumor clearance.

    Source: Cancer Cell
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SCIDirector
      SCIDirector

      SCI member Edgar Engleman and Postdoctoral scholar Ian Linde found when #neutrophils are activated they eliminate several types of tumors in laboratory mice. https://t.co/Z5ckngNSpo #ImmunoOncology https://t.co/b2Na5YkBJt

  • Mashup Score: 0
    Immuno-Oncology - 1 year(s) ago

    Sign Up for Email Get the latest news and education delivered to your inbox

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      Immuno-oncology is an ever evolving field. Get the latest clinical content on this topic and more with Clinical Guidance. https://t.co/oSprKnJNyy #ImmunoOncology #ClinicalGuidance https://t.co/6ERlW2QCMY

    • Profile photo of GoHealio
      GoHealio

      Immuno-oncology is an ever evolving field. Get the latest clinical content on this topic and more with Clinical Guidance. https://t.co/oTgY8rZXmf #ImmunoOncology #ClinicalGuidance https://t.co/gfsMXqUbsw

  • Mashup Score: 1
    Urothelial Carcinoma: Advances in Immuno-Oncology - 1 year(s) ago

    Urothelial Carcinoma: Advances in Immuno-Oncology Host: Jay D. Raman, MD, FACS Co-Hosts: Andrea Apolo, MD and Sima Porten, MD CME Available: auau.auanet.org/node/37325 At the conclusion of this act

    Source: SoundCloud
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of apolo_andrea
      apolo_andrea

      Great to chat with ⁦@urojdr⁩ & ⁦@SimaPorten⁩ about failed trials & the evolving landscape in #UrothelialCarcinoma #ImmunoOncology #BladderCancer ⁦@AmerUrological⁩ #AUAUniversity Podcast playlist online for free on SoundCloud https://t.co/Y4laq1WEsY

  • Mashup Score: 2
    CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia - 2 year(s) ago

    Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.The research — published in Journal of Clinical Oncology — is the largest study of CAR T cells in younger patients with B-cell ALL to date and may

    Source: www.healio.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of RenoHemonc
      RenoHemonc

      RT @HemOncToday: NEW STANDARD: CAR-T regimen for high-risk B-cell acute lymphoblastic leukemia? https://t.co/YAwFmT4iKO @JCO_ASCO #CARTsel…

    • Profile photo of HemOncToday
      HemOncToday

      NEW STANDARD: CAR-T regimen for high-risk B-cell acute lymphoblastic leukemia? https://t.co/YAwFmT4iKO @JCO_ASCO #CARTsell @StJude #ImmunoOncology #HemOnc #OncAlert @ASCO

  • Mashup Score: 1
    ESMO Immuno-Oncology Congress 2022: Registration - 2 year(s) ago

    The ESMO Immuno-Oncology Congress 2022 will take place onsite in Geneva, Switzerland and online in a virtual format

    Source: www.esmo.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno22: Last chance to register at reduced fees (5/10) - key opinion leaders presenting their latest findings & debating burning topics in #immunooncology https://t.co/c6Pu5L2TLq @BcellBruno @CoukosGeorge @VriesElisabeth @MarcoGerlinger @matsadoc @DrIgMelero @SamraTurajlic https://t.co/ceSo7vYMdc

Load More